When a press release says a biotech is "eligible to receive up to $2.2 billion" from a partner, almost none of that is money in the bank. The figure is the sum of every payment the deal could theoretically trigger over a decade or more, and the bulk of it is made of milestone payments — the contingent installments the industry nicknames "biobucks." Understanding a licensing deal means pulling that headline apart into the few dollars that are committed and the many that are merely conditional.

A typical biotech collaboration agreement has three economic layers. First is the upfront payment: cash (and sometimes an equity investment) paid at or near signing, the only portion that is non-contingent. Second are the milestone payments themselves, which are tiered by category — research milestones (e.g., selecting a development candidate), development and regulatory milestones (dosing a first patient, hitting a trial readout, securing a regulatory filing or approval), and commercial milestones (net sales crossing defined thresholds). Each milestone pays only if and when its event occurs. Third are royalties on net sales of any product that ultimately reaches market — usually "tiered," meaning the percentage steps up or down across sales bands. A concrete, SEC-filed example makes the layering legible. In a collaboration disclosed in a Form 8-K and described in its first-quarter 2025 results exhibit, Septerna, Inc. set out the architecture of an agreement with Novo Nordisk.

"Under the terms of the agreement, Septerna is eligible to receive approximately $2.2 billion from Novo Nordisk across an upfront payment and research, development and commercial milestone payments. This includes more than $200 million in upfront and near-term milestone payments. Septerna is also eligible to receive tiered royalties on global net sales of marketed products."— Septerna, Inc., Form 8-K Exhibit 99.1 (filed with the SEC), source

Read that disclosure the way a deal desk does. The $2.2 billion is the ceiling, not the consideration. Inside it, "more than $200 million in upfront and near-term milestone payments" is the portion within reach early; the remaining roughly $2 billion is the long tail of research, development, and commercial biobucks that pays out only as a partnered program advances. The release further states that the partner "will cover all R&D expenses for partnered programs under the collaboration," which is itself an economic term: cost coverage shifts the burn of the program off the smaller company's income statement. None of those later milestones is guaranteed, and in the industry most contingent milestones in a given deal are never earned, because candidates fail at the rates clinical development implies.

Why the headline number and the cash number diverge

The gap between "up to $2.2 billion" and "more than $200 million near-term" is the entire point of the structure for the paying partner. Contingent payments let an acquirer or licensor pay for de-risking as it happens rather than at signing: the bulk of consideration is owed only after the science, the regulators, or the market have validated the asset. For the receiving company, the upfront and near-term tranche is what funds operations now, while the milestone tail is optionality that may or may not convert. That is why a disciplined reading always separates the two — and why management itself separated them in the disclosure above, calling out the near-term figure distinctly from the total.

The structure also reshapes the recipient's balance sheet immediately, even before a single milestone is hit. In the same exhibit, Septerna reported it "Ended First Quarter 2025 with $398.2 million in Cash, Cash Equivalents and Marketable Securities" and stated it expected the upfront payment to "significantly extend its prior cash runway guidance of early 2028." That is the near-term cash doing its job: an upfront converts directly into runway, whereas biobucks are accounting and operational possibilities, not present resources. The distinction matters for anyone reading the filing as a financial document rather than a marketing one.

Where the real terms live

The press-release exhibit gives the shape; the binding terms live in the licensing or collaboration agreement itself, typically filed as a separate exhibit (often with portions redacted as confidential) under the same 8-K. Two reporting points follow. First, the only number with a fixed payment obligation is the upfront, plus any specifically "near-term" milestones management identifies; everything labeled "potential," "eligible to receive," or "up to" is contingent by definition. Second, the royalty line is its own layer of contingency on top of the milestones — royalties accrue only if a product is approved and sold, and "tiered" royalties vary by net-sales band, so even the royalty take is a function of commercial outcomes nobody can promise at signing.

It is also worth noting how the accounting treats these layers, because the income statement does not recognize the headline figure either. Under revenue-recognition rules for collaboration and licensing arrangements, an upfront and licensing consideration is allocated to the performance obligations in the contract and recognized over time or at points in time as those obligations are satisfied; variable consideration such as milestone payments is generally constrained and not recognized as revenue until it is probable that a significant reversal will not occur, which for development and regulatory milestones is typically when the milestone is achieved or near-certain. The practical consequence is that the "up to $2.2 billion" almost never appears as revenue in any single period, and a milestone hits the financials only when the underlying event is essentially in hand. The disclosure framework and the accounting framework point the same way: the contingent layers are recognized as they convert, not when the deal is signed.

The practical discipline, then, is simple to state. When a biotech announces a deal, find the 8-K on sec.gov and read the exhibit, not the headline. Separate the upfront (cash now) from the milestone total (biobucks, contingent), note whether the partner is also covering R&D expense, and treat the royalty as a further conditional layer. The deal value that gets quoted is the sum of best cases stacked end to end; the deal value that funds the company is the upfront. Both are disclosed — the structure is designed to be read — but only one of them is money the company actually has.